Features | Partner Sites | Information | LinkXpress
Sign In
FOCUS DIAGNOSTICS, INC.
RANDOX LABORATORIES
SEEGENE

Automated Microscope Alerts Diagnosticians to Possible Cell Anomalies

By Labmedica International staff writers
Posted on 10 Jan 2012
Anomalies Image: The Ikoniscope Digital Microscopy System (Photo courtesy of Ikonisys ).
Anomalies Image: The Ikoniscope Digital Microscopy System (Photo courtesy of Ikonisys ).
An automated microscope system runs its own tests and alerts diagnosticians to possible cell anomalies.

The Ikoniscope digital microscopy system provides fully automated slide handling, complete slide scanning, and real-time image capture and analysis. It enumerates and classifies cellular nuclei completely unattended so technologists can focus on sample classification and interpretation.

The Ikonisys (New Haven, CT, USA) system consists of three parts: a robotic handling apparatus, the reagents needed to run the tests, and image processing software to identify problematic proteins or chromosomes.

The robust platform supports the automation of standard tests, as well as Ikonisys' advanced rare cell detection applications. Both provide a noninvasive, accurate alternative to existing technologies.

To use the Iconoscopes microscope system, the lab technician merely needs to load slides with the cell samples, introduce the reagent that will make abnormal cells fluoresce, place up to 25 slides into a cassette, slide the cassette into the machine, and push a button. The robotic handling system will remove each slide one by one and scan the cells to see which ones are abnormal. The machine tells the technician which cells looked suspicious, and he can then spend a couple minutes checking only those.

Petros Tsipouras, professor of biology at the University of Athens (Greece) and Ikonisys chairman and CEO, said that the system could lead to a noninvasive alternative to amniocentesis or chorionic villus sampling to check fetuses for chromosomal abnormalities that could indicate Down’s Syndrome.

The system could also look for cancer cells shed by a tumor and circulating in the bloodstream, even when the tumor is too small to image. Such a test could be a useful backup to the prostate specific antigen (PSA) tests given to men to look for prostate cancer that would cut down on unnecessary biopsies.

The company has begun marketing the automated system, starting with a test for bladder cancer and another for abnormalities on amniocytes that would indicate birth defects. It plans to introduce another test, based on a third-party reagent, to look for signs of breast cancer.

Ikonisys has launched a clinical laboratory for its rare-cell-based tests. Under Food and Drug Administration (FDA; Silver Spring, MD, USA) “home brew” rules, the company can use its tests in-house before it receives FDA approval to sell to others.

Related Links:

Ikonisys
University of Athens
Food and Drug Administration



GREINER-BIO-ONE
PURITAN MEDICAL
ADVANCED INSTRUMENTS
BioConferenceLive

Channels

Clinical Chemistry

view channel
Image: The ICON 25 hCG point-of-care pregnancy test (Photo courtesy of Beckman Coulter).

Pregnancy Tests Evaluated During Early Gravidity

The predominant hormone human chorionic gonadotropin (hCG) variant in urine, hCG β core fragment (hCGβcf), has been demonstrated to cause false-negative results in qualitative point-of-care (POC) hCG devices.... Read more

Genetic Tests

view channel
Image: The Quant-iT PicoGreen dsDNA Assay Kit (Photo courtesy of Invitrogen).

Blood Test Provides Rapid Method of Detecting Solid Cancers

Circulating tumor DNA (ctDNA) is a promising biomarker for noninvasive assessment of cancer burden, but existing detection methods have insufficient sensitivity or patient coverage for broad clinical applicability.... Read more

Pathology

view channel
Image: Micrograph showing prostatic acinar adenocarcinoma, the most common form of prostate cancer (Photo courtesy of Zephron).

New Test Could Accurately Predict Prostate Cancer Recurrence

A test based on genetic signature and tumor oxygen levels, which boost the test’s accuracy, can predict whether a man is at high risk of prostate cancer recurrence. Prostate cancer is the most common... Read more

Industry News

view channel

Roche and Hitachi Renew Alliance in Diagnostics

Roche (Basel, Switzerland) and Hitachi (Tokyo, Japan) have renewed their alliance in the diagnostics business by 10-years for the joint development and manufacture of the next generation of instruments and workflow automation solutions for medical laboratories. The renewed alliance marks a significant milestone towards... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.